NCCN Guidelines Insights: Colorectal Cancer Screening, Version 2.2020.

Szczegóły
Abstrakt

Tytuł:: NCCN Guidelines Insights: Colorectal Cancer Screening, Version 2.2020.
Autorzy:: Provenzale D; Duke Cancer Institute.
Ness RM; Vanderbilt-Ingram Cancer Center.
Llor X; Yale Cancer Center/Smilow Cancer Hospital.
Weiss JM; University of Wisconsin Carbone Cancer Center.
Abbadessa B; UC San Diego Moores Cancer Center.
Cooper G; Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute.
Early DS; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine.
Friedman M; Moffitt Cancer Center.
Giardiello FM; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
Glaser K; Roswell Park Comprehensive Cancer Center.
Gurudu S; Mayo Clinic Cancer Center.
Halverson AL; Robert H. Lurie Comprehensive Cancer Center of Northwestern University.
Issaka R; Fred Hutchinson Cancer Center/Seattle Cancer Care Alliance.
Jain R; Fox Chase Cancer Center.
Kanth P; Huntsman Cancer Institute at the University of Utah.
Kidambi T; City of Hope National Medical Center.
Lazenby AJ; Fred & Pamela Buffett Cancer Center.
Maguire L; University of Michigan Rogel Cancer Center.
Markowitz AJ; Memorial Sloan Kettering Cancer Center.
May FP; UCLA Jonsson Comprehensive Cancer Center.
Mayer RJ; Dana-Farber/Brigham and Women's Cancer Center | Massachusetts General Hospital Cancer Center.
Mehta S; Abramson Cancer Center at the University of Pennsylvania.
Patel S; University of Colorado Cancer Center.
Peter S; O'Neal Comprehensive Cancer Center at UAB.
Stanich PP; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute.
Terdiman J; UCSF Helen Diller Family Comprehensive Cancer Center; and.
Keller J; National Comprehensive Cancer Network.
Dwyer MA; National Comprehensive Cancer Network.
Ogba N; National Comprehensive Cancer Network.
Źródło:: Journal of the National Comprehensive Cancer Network : JNCCN [J Natl Compr Canc Netw] 2020 Oct 01; Vol. 18 (10), pp. 1312-1320. Date of Electronic Publication: 2020 Oct 01.
Typ publikacji:: Journal Article; Practice Guideline; Research Support, Non-U.S. Gov't
Język:: English
Imprint Name(s):: Publication: 2010- : Cold Spring Harbor, N.Y. : Harborside Press
Original Publication: Sudbury, MA : Jones and Bartlett Publishers, c2003-
MeSH Terms:: Colorectal Neoplasms*/diagnosis
Colorectal Neoplasms*/epidemiology
Early Detection of Cancer*
Humans ; Mass Screening
References:: Gastroenterology. 2020 Jan;158(2):341-353. (PMID: 31394082)
Ann Intern Med. 2018 Sep 18;169(6):405-406. (PMID: 29987330)
Ann Intern Med. 2008 Nov 4;149(9):627-37. (PMID: 18838716)
J Clin Oncol. 2016 Jul 20;34(21):2501-8. (PMID: 27247217)
Gastroenterology. 2020 Mar;158(4):862-874.e8. (PMID: 31376388)
J Clin Oncol. 2014 Nov 1;32(31):3568-74. (PMID: 25273035)
Cancer. 2018 Jul 15;124(14):2964-2973. (PMID: 29846933)
Cancer. 2015 Jul 1;121(13):2281-5. (PMID: 25763558)
Am Soc Clin Oncol Educ Book. 2018 May 23;38:88-100. (PMID: 30231343)
CA Cancer J Clin. 2011 Jul-Aug;61(4):212-36. (PMID: 21685461)
Ann Oncol. 2020 Mar;31(3):352-368. (PMID: 32067678)
CA Cancer J Clin. 2018 Jul;68(4):250-281. (PMID: 29846947)
J Natl Cancer Inst. 2007 Oct 3;99(19):1471-83. (PMID: 17895473)
CA Cancer J Clin. 2020 Jan;70(1):7-30. (PMID: 31912902)
Ann Intern Med. 2019 Nov 19;171(10):756-764. (PMID: 31569235)
Am J Clin Oncol. 2011 Dec;34(6):573-80. (PMID: 21217399)
Gastroenterology. 2012 Sep;143(3):844-857. (PMID: 22763141)
J Clin Oncol. 2018 Jan 1;36(1):83-93. (PMID: 29112463)
Gastroenterology. 2020 Mar;158(4):852-861.e4. (PMID: 31302144)
Nutrients. 2018 Aug 16;10(8):. (PMID: 30115827)
CA Cancer J Clin. 2018 Jan;68(1):31-54. (PMID: 29160902)
CA Cancer J Clin. 2017 May 6;67(3):177-193. (PMID: 28248415)
N Engl J Med. 2016 Aug 25;375(8):794-8. (PMID: 27557308)
Cancer. 2018 Jul 15;124(14):2974-2985. (PMID: 29846942)
Gastroenterology. 2019 Jul;157(1):137-148. (PMID: 30930021)
Am J Gastroenterol. 2009 Mar;104(3):739-50. (PMID: 19240699)
MMWR Morb Mortal Wkly Rep. 2012 Jan 27;61(3):41-5. (PMID: 22278157)
Cancer Epidemiol Biomarkers Prev. 2009 Dec;18(12):3362-7. (PMID: 19959683)
JAMA. 2018 May 15;319(19):2021-2031. (PMID: 29800214)
Gastroenterology. 2018 Oct;155(4):950-954. (PMID: 30138614)
Clin Gastroenterol Hepatol. 2018 Oct;16(10):1541-1544. (PMID: 30114484)
Am J Gastroenterol. 2020 Mar;115(3):415-434. (PMID: 32039982)
Br J Gen Pract. 2011 May;61(586):e231-43. (PMID: 21619747)
Br J Cancer. 2019 Jul;121(1):86-94. (PMID: 31114018)
Cancer. 2012 May 1;118(9):2338-66. (PMID: 22460733)
JAMA Surg. 2015 Jan;150(1):17-22. (PMID: 25372703)
J Natl Cancer Inst. 2000 Dec 6;92(23):1888-96. (PMID: 11106680)
Gut. 2012 Aug;61(8):1180-6. (PMID: 22110052)
Gut. 2019 Oct;68(10):1820-1826. (PMID: 31097539)
Ann Oncol. 2011 Sep;22(9):1958-1972. (PMID: 21307158)
Am J Epidemiol. 2015 Jun 1;181(11):832-45. (PMID: 25888582)
Lancet Oncol. 2015 Dec;16(16):1599-600. (PMID: 26514947)
CA Cancer J Clin. 2017 Jan;67(1):7-30. (PMID: 28055103)
CA Cancer J Clin. 2020 May;70(3):145-164. (PMID: 32133645)
Ann Intern Med. 2016 Jun 21;164(12):814-25. (PMID: 27064482)
Cancer Epidemiol Biomarkers Prev. 2009 Jun;18(6):1695-8. (PMID: 19505901)
Ann Epidemiol. 2015 Mar;25(3):208-213.e1. (PMID: 25721748)
Pediatr Blood Cancer. 2019 Nov;66(11):e27941. (PMID: 31348592)
CA Cancer J Clin. 2008 May-Jun;58(3):130-60. (PMID: 18322143)
J Natl Cancer Inst. 2000 Nov 1;92(21):1740-52. (PMID: 11058617)
Grant Information:: K08 CA241296 United States CA NCI NIH HHS; L32 MD012892 United States MD NIMHD NIH HHS; UL1 TR001863 United States TR NCATS NIH HHS
Entry Date(s):: Date Created: 20201006 Date Completed: 20211104 Latest Revision: 20211104
Update Code:: 20240105
PubMed Central ID:: PMC8311627
DOI:: 10.6004/jnccn.2020.0048
PMID:: 33022639
: Czasopismo naukowe

The NCCN Guidelines for Colorectal Cancer (CRC) Screening describe various colorectal screening modalities as well as recommended screening schedules for patients at average or increased risk of developing sporadic CRC. They are intended to aid physicians with clinical decision-making regarding CRC screening for patients without defined genetic syndromes. These NCCN Guidelines Insights focus on select recent updates to the NCCN Guidelines, including a section on primary and secondary CRC prevention, and provide context for the panel's recommendations regarding the age to initiate screening in average risk individuals and follow-up for low-risk adenomas.

Informacja